PubMed · 17010268
Update on dermal substitutes.
Abstract
Tissue-engineered biological dressings offer promise in the treatment of burns, chronic ulcers, donor site and other surgical wounds, and a variety of dermatologic conditions. Despite this promise, cellular tissue-engineered products such a Dermagraft and Apligraf have suffered setbacks in recent years with a lower market share than the commercial promoters of these products anticipated. AlloDerm acellular dermal matrix, an older technology than these cell-based products, has made strong progress in winning over clinicians in various disciplines. Similarly, Integra Bilayer Matrix Wound Dressing (BMWD) continues to gain acceptance beyond its original burn audience. A review on the products is offered.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Michael Ehrenreich, Zbigniew Ruszczak. 2006. Update on dermal substitutes.. https://pubmed.ncbi.nlm.nih.gov/17010268/
Cite the original work for its findings. Save a collection to share your selection of sources.